Safety of mRNA vaccination for COVID ‐19 in children with polyethylene glycol ( PEG )‐asparaginase allergy
Pediatric Allergy and Immunology · 2023
DOI: 10.1111/pai.13939 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Allergy and Immunology, 2023. Verfasst von Rebecca Doyle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Health Queensland Hospital and Health Service, South Brisbane, Australia. Hauptthemen laut MEDLINE: COVID-19, Drug Hypersensitivity, Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Health Queensland Hospital and Health Service, South Brisbane, Australia.
- University of Queensland, School of Nursing, Midwifery and Social Work, St Lucia, Australia.
- University of Queensland, Centre for Clinical Research, Herston, Australia.
ORCID-Profile: Rebecca Doyle, Sophie Willcocks
Zitieren
APA
Doyle, R., Melo, M., Teoh, C., Wen, S., & Willcocks, S. (2023). Safety of mRNA vaccination for COVID ‐19 in children with polyethylene glycol ( PEG )‐asparaginase allergy. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13939
Vancouver
Doyle R, Melo M, Teoh C, Wen S, Willcocks S. Safety of mRNA vaccination for COVID ‐19 in children with polyethylene glycol ( PEG )‐asparaginase allergy. Pediatric Allergy and Immunology. 2023. doi:10.1111/pai.13939
BibTeX
@article{Doyle2023,
author = {Doyle, Rebecca and Melo, Mariana and Teoh, Cindy and Wen, Sophie and Willcocks, Sophie},
title = {Safety of mRNA vaccination for COVID ‐19 in children with polyethylene glycol ( PEG )‐asparaginase allergy},
journal = {Pediatric Allergy and Immunology},
year = {2023},
doi = {10.1111/pai.13939}
}
EUVIMED